Prostate Cancer

Talazoparib in combination with enzalutamide showed a 55% reduction in the risk of disease progression or death for patients with metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene mutations in the phase 3 TALAPRO-2 trial.

There was no difference in second primary cancer risk among older adult male patients treated with intensity-modulated radiotherapy (IMRT) vs 3-dimensional conformal radiation therapy for prostate cancer.

An analysis of patients with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) deficiency mutations showed that patients with BRCA mutations had poor outcomes compared with those without BRCA mutations and those with non-BRCA HRR mutations.

Research presented at the American Society of Clinical Oncology Annual Meeting found prostate-specific membrane antigen ligand positron emission tomography (PSMA-PET) to be associated with worse overall survival in prostate cancer without distant metastasis based on conventional imaging.

The FDA has approved flotufolastat F 18 injection for positron emission tomography of prostate-specific membrane antigen–positive lesions in certain men with prostate cancer.

Olaparib plus abiraterone and prednisone or prednisolone already is approved in the European Union and several other countries.

Results are based off of data from the Florida Behavioral Risk Factor Surveillance System.

Researchers suggest socioeconomic status (SES) be considered in prognostic algorithms going forward.

No benefit was found in low-risk patients who underwent pelvic lymph node dissection (PLND).

The presence of certain comorbidities prior to androgen deprivation therapy (ADT) for prostate cancer may be associated with a greater risk of cardiovascular events after starting ADT, recent research found.

A cross-sectional survey of patient preferences found that the out-of-pocket cost of treatment was the most impactful attribute for patients when choosing an androgen deprivation therapy (ADTs) for their prostate cancer.

The use of active surveillance for indolent prostate cancer cases continues to rise in the United States, but rates of use are lower in minority groups, low-income groups, and patients in rural areas, a recent study found.

There are various areas across different patient care and support perspectives that offer opportunities to improve value-based care in oncology, said Ryan Huey, MD, gastrointestinal medical oncologist at MD Anderson Cancer Center in Houston, Texas.

Reducing health care disparities may require shifting from providing equal care to providing equitable care.

Mike Lattanzi, MD, genitourinary medical oncologist, Texas Oncology, discusses the importance of keeping pace with precision oncology options as rates for prostate cancer increase.

Treatment with relugolix and concomitant therapies for prostate cancer showed similar safety and efficacy to relugolix alone in a recent study.

Patients with prostate cancer who were treated with brachytherapy boost showed improved survival compared with those treated with external beam radiotherapy in a recent study.

Extended follow-up data from the ProtecT trial highlight the importance of weighing the risks associated with radical treatment versus active surveillance for newly diagnosed localized prostate cancer.

The findings, published in the Journal of the National Comprehensive Cancer Network, add to the evidence that the shift to precision medicine is built on data that have not included sufficient numbers of patients of color.

The new report found polygenic risk scores likely will not help identify patients at highest risk.

Rates of active surveillance for low-risk prostate cancer have improved nationally but vary locally and remain subpar overall, according to findings from a study published in JAMA Network Open.

Overall survival, cancer-specific survival and progression-free survival were all negatively affected by elevated C-reactive protein levels, this study found.

Relugolix was frequently used in combination with other medications for prostate cancer in patients both new to androgen-deprivation therapy and continuing androgen-deprivation therapy in a real-world study.

The study found 143 loci where somatic copy numbers were varied based on genetic ancestry.

A randomized controlled trial found that the use of a rectal spacer may help mitigate the gastrointestinal (GI) toxicity associated with hypofractionated radiation therapy for prostate cancer.